BrUOG-H-N-229-RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer: A PHASE I STUDY- Novartis CRAD001CUS134T.
Latest Information Update: 26 Apr 2019
At a glance
- Drugs Everolimus (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Feb 2012 Planned end date changed from 1 Jun 2012 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 11 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Feb 2010 New trial record